Innoviva (NASDAQ:INVA) Stock Picked Up by Analysts at Piper Sandler

Innoviva logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Piper Sandler initiated coverage of Innoviva with an “overweight” rating and a $29 price target, implying 58.47% upside from the prior close.
  • Analyst sentiment is generally positive: Innoviva has a “Moderate Buy” consensus rating from six Buy ratings and one Hold, with an average price target of $37.
  • Innoviva missed quarterly expectations, reporting a loss of $1.03 per share versus consensus earnings of $0.52 and revenue of $106.12 million versus estimates of $115.31 million.
  • Five stocks we like better than Innoviva.

Investment analysts at Piper Sandler assumed coverage on shares of Innoviva (NASDAQ:INVA - Get Free Report) in a report issued on Wednesday, MarketBeat.com reports. The brokerage set an "overweight" rating and a $29.00 price target on the biotechnology company's stock. Piper Sandler's price objective would indicate a potential upside of 58.47% from the company's previous close.

Other analysts also recently issued reports about the company. Weiss Ratings raised Innoviva from a "hold (c+)" rating to a "buy (b)" rating in a research report on Monday, November 9th. Zacks Research upgraded shares of Innoviva from a "strong sell" rating to a "hold" rating in a report on Monday, August 31st. Cantor Fitzgerald decreased their target price on shares of Innoviva from $36.00 to $34.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Wall Street Zen lowered shares of Innoviva from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Oppenheimer lowered their target price on shares of Innoviva from $35.00 to $34.00 and set an "outperform" rating for the company in a research note on Thursday, November 5th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Innoviva currently has an average rating of "Moderate Buy" and an average price target of $37.00.

Read Our Latest Stock Report on Innoviva

Innoviva Price Performance

INVA stock opened at $18.30 on Wednesday. The business has a fifty day moving average of $20.58 and a two-hundred day moving average of $21.84. The company has a quick ratio of 14.58, a current ratio of 15.44 and a debt-to-equity ratio of 0.23. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 5.33, a price-to-earnings-growth ratio of 2.65 and a beta of 0.38. Innoviva has a 52-week low of $18.28 and a 52-week high of $25.15.

Innoviva (NASDAQ:INVA - Get Free Report) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of $0.52 by ($1.55). Innoviva had a net margin of 44.13% and a return on equity of 22.91%. The business had revenue of $106.12 million during the quarter, compared to analysts' expectations of $115.31 million. As a group, research analysts anticipate that Innoviva will post 2.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in INVA. BlackRock Inc. purchased a new stake in Innoviva during the 2nd quarter worth about $77,562,000. Dimensional Fund Advisors LP raised its position in Innoviva by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company's stock valued at $103,366,000 after purchasing an additional 76,026 shares in the last quarter. Bank of America Corp DE acquired a new stake in Innoviva in the 2nd quarter valued at about $37,873,000. Deutsche Bank AG acquired a new stake in Innoviva in the 2nd quarter valued at about $20,847,000. Finally, William Blair Investment Management LLC boosted its stake in shares of Innoviva by 29.7% in the 3rd quarter. William Blair Investment Management LLC now owns 832,881 shares of the biotechnology company's stock valued at $17,665,000 after buying an additional 190,705 shares during the period. 99.12% of the stock is currently owned by institutional investors and hedge funds.

About Innoviva

(Get Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

Recommended Stories

Analyst Recommendations for Innoviva (NASDAQ:INVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Innoviva Right Now?

Before you consider Innoviva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.

While Innoviva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines